---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-006473"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:02:45.423031+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IMDX raises $26M in registered direct offering; funds heart transplant rejection test development

## Summary
- Gross proceeds ~$26M from 4,525,976 shares/pre-funded warrants at $5.75/unit; net proceeds ~$24.5M.
- Proceeds to expand GraftAssure product line into heart transplant rejection testing, beyond current kidney focus.
- Bio-Rad Laboratories, significant shareholder, participated on same terms as other institutional investors.
- Offering closed Feb 12, 2026; Lake Street Capital Markets acted as sole placement agent.

## SEC filing metadata
- accession: 0001493152-26-006473
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/0001493152-26-006473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-006473
- JSON: https://secwatch.observer/filing/0001493152-26-006473.json
- Plain text: https://secwatch.observer/filing/0001493152-26-006473.txt

## Key facts
- Material Agreements
  Insight Molecular Diagnostics Inc. entered into Placement Agency Agreement with Lake Street Capital Markets, LLC (effective 2026-02-10).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Lake Street Capital Markets, LLC
  - Effective: 2026-02-10
  source text: The Company entered into a placement agency agreement (the “ Placement Agency Agreement ”), dated as of February 10, 2026, with Lake Street Capital Markets, LLC (the “ Placement Agent ”), pursuant to which the Placement Agent agreed to serve as the placement agent for the Company in connection with the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/0001493152-26-006473-index.htm
- Material Agreements
  Insight Molecular Diagnostics Inc. entered into Purchase Agreements with certain institutional investors valued at approximately $24.5 million (effective 2026-02-10).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $24.5 million
  - Effective: 2026-02-10
  source text: On February 10, 2026, Insight Molecular Diagnostics Inc. (the “ Company ”) entered into securities purchase agreements (the “ Purchase Agreements ”) with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,482,498 shares (the “ Shares ”) of the Company’s common stock, no par value per share (the “ Common Stock ”), and (ii) Pre-Funded Warrants (the “ Pre-Funded Warrants ”) to purchase up to 1,043,478 shares of Common Stock (the “ Pre-Funded Warrant Shares ”) in a registered direct offering (the “ Offering ”), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-281159), a base prospectus and prospectus supplement relating to the Offering (the “ Prospectus Supplement ”), in each case filed with the Securities and Exchange Commission.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/0001493152-26-006473-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.